Proteogenix는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다.

제품 설명 

SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

제품 번호

PX-COV-P074

제품 특징

Description of SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

General information on SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

Lineage B.1.1.529 was reported to WHO in late November 2021 in South Africa. This variant of SARS-CoV-2 accumulates an unprecedented high number of mutations on the spike protein, and especially receptor binding domain (RBD), compared to former variants involved in the Covid-19 pandemic.
The reported mutations are the following : A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211-212, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F.
The consequences of these new mutations are not yet clear. Some of them had been detected in other variants. K417N and N501Y are typical mutations of the Beta variant from South Africa. S477N had been reported in a variant found in the USA, detected in December 2020, lineage B.1.526.2. Many other mutations are new to the scientific community and need to be studied. According to preliminary results, this new variant might be related to an increased reinfection rate. There are also evidences for a higher growth of the virus.
The PCR tests that have been deployed for other variants still detect it. The efficiency of market vaccines on the omicron variant is currently studied.
After spreading in all South African regions, the variant has been reported in other African countries such as Botswana and then in Europe.
More studies are necessary to determine the precise properties of this variant, especially the impacts of its unreported mutations on transmissibility and the severity its cases of Severe Acute Respiratory Syndrome.

QC & Validation Data

SDS-PAGE for SARS-CoV-2 RBD of Spike protein– lineage B.1.1.529 – Omicron Variant

Publications

- Hubert Bernauer, Anja Schlör, Josef Maier, Norbert Bannert, Katja Hanack, Daniel Ivanusic, tANCHOR fast and cost-effective cell-based immunization approach with focus on the receptor-binding domain of SARS-CoV-2, Biology Methods and Protocols, Volume 8, Issue 1, 2023, bpad030, https://doi.org/10.1093/biomethods/bpad030

- Winklmeier S, Rübsamen H, Özdemir C, Wratil PR, Lupoli G, Stern M, Schneider C, Eisenhut K, Ho S, Wong HK, Taskin D, Petry M, Weigand M, Eichhorn P, Foesel BU, Mader S, Keppler OT, Kümpfel T and Meinl E (2024) Intramuscular vaccination against SARS-CoV-2 transiently induces neutralizing IgG rather than IgA in the saliva. Front. Immunol. 15:1330864. doi: 10.3389/fimmu.2024.1330864

ProteoGenix의 모든 제품들을 만나보세요!

• Proteins
• 
  
• Primary antibodies
• 
  
• Secondary antibodies
• 
  
• ELISA assay kits
• 
  
• Cell separation media
• 
  
• Other products

Proteogenix - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"